Hospital-onset SARS-CoV-2 infection during omicron linked to morbidity
Jul 15, 2024
Hospital-onset SARS-CoV-2 remained associated with increased morbidity and mortality during the omicron era.
18.3 percent of physicians reported PTSD during COVID-19 pandemic
Jul 25, 2024
An increased likelihood was seen for female physicians, older physicians, and trainees, and for emergency department doctors.
15 million COVID-19 vaccine doses wasted in U.S. since March 1
Sep 02, 2021
Reasons why doses may be marked as wasted include a cracked vial, an error diluting the vaccine or a freezer malfunction.
Prolonged SARS-CoV-2 risk varies across immunosuppressive conditions
Jan 31, 2024
Severely immunocompromised individuals had greater SARS-CoV-2 evolution and a higher risk for developing resistance against therapeutic mAbs.
CDC calls emergency meeting on heart inflammation link to COVID-19 vaccines
Jun 11, 2021
The agency has identified 226 reports so far that may meet its ‘working case definition’ of myocarditis and pericarditis.
Subcutaneous mAb may benefit high-risk outpatients with COVID-19
Apr 12, 2022
SC casirivimab and imdevimab were linked to reduced 28-day hospitalization or death for high-risk outpatients with mild to moderate COVID-19.
Guillain-Barré syndrome may be triggered by SARS-CoV-2 infection
Sep 24, 2021
“Our study shows that COVID-19 may precede Guillain-Barré syndrome in rare cases,” a coauthor said in a statement, “but the existence of a true association or causal relation still needs...
SARS-CoV-2 mAbs continued to be used after FDA deauthorization
Aug 30, 2022
More than 158,000 doses of bamlanivimab-etesevimab and casirivimab-imdevimab were used after deauthorization on Jan. 24, 2022.
Update: Masks may reduce SARS-CoV-2 infection in community settings
May 16, 2023
An updated review of the evidence shows a small reduction in risk for SARS-CoV-2 infection with mask use versus no mask use.
SARS-CoV-2 antibodies may persist nine months after infection
Jul 26, 2021
Antibody levels appear to remain positive for up to nine months after severe acute respiratory syndrome coronavirus 2 infection, according to a study published online July 19 in Nature Communications.